US 7,847,061 B2
Treatment of short bowel syndrome patients with colon-in-continuityGeneral
US 7,847,061 B2
Treatment of short bowel syndrome patients with colon-in-continuity
Tech Center:
1600 Biotechnology and Organic Chemistry
Examiner:
Andrew D Kosar
Art Unit:
1654 Fermentation, Microbiology, Isolated and Recombinant Proteins/Enzyme
Agent:
Inventors:
Elizabeth Lemaire Sanguinetti; Thomas B. Marriott; Jennifer Lopansri; Consuelo Maria Blosch
Assignee:
Priority:
11/01/04
Filed:
11/01/05
Granted:
12/07/10
Expiration:
11/01/24
Abstract
Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Cooperative Patent Classification (CPC)
A61A61K9/0019A61P1/00A61B5/4222A61K